Pfizer CEO says $7 billion cash ready for bolt‑on acquisitions and dividend will stay intact

During its second‑quarter earnings call, analysts asked Pfizer if the company would increase M&A spending as rivals rush to buy biotech assets.

CEO Albert Bourla replied that Pfizer currently has about $7 billion available for bolt‑on deals and that the company will keep its long‑term dividend, with plans to raise it after a key loss‑of‑exclusivity period.

He highlighted that Pfizer has already spent roughly $80 billion on acquisitions since 2022, citing purchases such as Seagen for about $44.6 billion, Biohaven’s migraine portfolio for $12.6 billion, and Metsera for $10 billion.

Bourla said the cash on hand could be used for opportunities in oncology, immuno‑inflammation or primary‑care areas like obesity, underscoring confidence in the company’s growth strategy.